Boston Scientific (NYSE:BSX) Updates Q2 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.820-0.840 for the period, compared to the consensus earnings per share estimate of 0.860. The company issued revenue guidance of $5.3 billion-$5.4 billion, compared to the consensus revenue estimate of $5.6 billion. Boston Scientific also updated its FY 2026 guidance to 3.340-3.410 EPS.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research report on Monday, February 2nd. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a report on Thursday. Robert W. Baird lowered their target price on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a report on Thursday. BTIG Research lowered their target price on shares of Boston Scientific from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Oppenheimer set a $90.00 price target on Boston Scientific in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Stock Up 1.6%

Shares of NYSE:BSX opened at $65.89 on Friday. The firm has a fifty day moving average price of $68.71 and a two-hundred day moving average price of $86.02. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a one year low of $59.38 and a one year high of $109.50. The company has a market cap of $97.93 billion, a price-to-earnings ratio of 27.57, a PEG ratio of 1.03 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts anticipate that Boston Scientific will post 3.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.34% of the stock is owned by corporate insiders.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat on sales and EPS: BSX reported roughly $5.20B in Q1 revenue (up ~11.6% YoY) and adjusted EPS of $0.80, topping Street sales and matching/edging EPS expectations—showing continued demand for core cardiology devices. Article Title
• Positive Sentiment: Shares rallied after the “reset”: the market interpreted the combination of a beat plus a deliberate guidance reset as a potential reset-for-outperformance trade, driving intraday gains following the release. Article Title
• Positive Sentiment: Elevated bullish options flow: traders bought a high volume of BSX call options around earnings, signaling speculative/hedged bullish positioning into the post-earnings move. Article Title
• Neutral Sentiment: Analysts cut price targets but largely kept buy/overweight ratings—banks trimmed PTs (Barclays, Jefferies, Truist, Baird, Needham) reflecting the lower guide while still pointing to mid/long-term upside. This reduces near-term sentiment but preserves institutional support. Article Title
• Neutral Sentiment: Street views call the guidance reset “prudent” and expect a Q2 trough; some analysts see the pullback as a buying opportunity if long-term growth drivers (EP, structural heart, etc.) remain intact. Article Title
• Negative Sentiment: Guidance cut and trimmed growth: management lowered FY2026 EPS and revenue guidance, citing specific product/segment headwinds—this is the primary reason for elevated volatility and lowered Street estimates. Article Title
• Negative Sentiment: Multiple securities class-action and investor-alert filings and law-firm investigations tied to the July 2025–Feb 2026 period create legal overhang and could increase uncertainty/expense for shareholders. Article Title
• Negative Sentiment: Short-term downside signals: some outlets flagged BSX hitting 52-week lows and several firms further trimmed forecasts—heightening near-term technical/psychological pressure. Article Title

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sunbelt Securities Inc. raised its stake in Boston Scientific by 33.0% in the fourth quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 350 shares in the last quarter. Compound Planning Inc. raised its stake in Boston Scientific by 14.7% in the fourth quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider’s stock valued at $1,471,000 after purchasing an additional 1,978 shares in the last quarter. Axxcess Wealth Management LLC raised its stake in Boston Scientific by 130.9% in the fourth quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider’s stock valued at $2,703,000 after purchasing an additional 16,068 shares in the last quarter. Corient Private Wealth LLC raised its stake in Boston Scientific by 11.1% in the fourth quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider’s stock valued at $22,238,000 after purchasing an additional 24,194 shares in the last quarter. Finally, Strive Financial Group LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $1,499,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.